

## Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukemia


Sandra W. Cowan-Jacob,<sup>\*</sup> Gabriele Fendrich, Andreas Floersheimer, Pascal Furet, Janis Liebetanz, Gabriele Rummel, Paul Rheinberger, Mario Centeleghe, Dorian Fabbro and Paul W. Manley

Novartis Institutes for Biomedical Research, Basel, , Switzerland. E-mail:  
sandra.jacob@novartis.com


### **Supplementary material**

Difference Fouriers for ligands in each of the crystal structures presented in the article.


**Figure S1.** Difference Fourier contoured at  $2.5 \sigma$  (blue mesh) for imatinib (yellow carbon, blue nitrogen, red oxygen) in complex with human Abl kinase.




**Figure S2.** Difference Fourier contoured at  $2.5 \sigma$  (blue mesh) for NVP-AEG082 (yellow carbon, blue nitrogen, red oxygen) in complex with Abl kinase.



**Figure S3.** Difference Fourier contoured at  $2.5 \sigma$  (blue mesh) for NVP-AFN941 (yellow carbon, blue nitrogen, red oxygen) in complex with Abl kinase.



**Figure S4.** Difference Fourier contoured at  $2.5 \sigma$  (blue mesh) for NVP-AFG210 (yellow carbon, blue nitrogen, red oxygen, green fluorine) in complex with Abl kinase.



**Figure S5.** Difference Fourier contoured at  $2.5 \sigma$  (blue mesh) for PD180970 (yellow carbon, blue nitrogen, red oxygen, green fluorine, magenta chlorine) in complex with Abl kinase.

